Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sympathetic Mechanisms in Obesity and Hypertension
NCT05312892Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of moxonidine in obesity, hypertension (HTN), sponsored by Vanderbilt University Medical Center. Started May 2022; status: recruiting.
02
Drugs
moxonidine
03
Conditions
obesityhypertension (HTN)
Beyond the preview
Go deeper on NCT05312892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312892.